MGC Pharmaceuticals - MXC(ASX) News & Expert Insights from Stockhead

MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America. The company’s current phytomedicine range includes CannEpil, an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, and CogniCann, a treatment to improve quality of life in dementia patients. Both products are certified as Investigational Medical Products in the EU, and emerge from MGC’s euGMP formulation facility.

MGC has a full seed to pharma operation, from proprietary genetics through to the final phytomedicines undergoing clinical trials and produced under the strictest manufacturing conditions in the world. Because of this full hold on the supply chain, MGC is also a supplier of multiple phytocannabinoid products, from genetics via seed or tissue culture , through cosmetics and nutraceuticals, all the way to final medications, and phytocannabinoid active pharmaceutical ingredients (API).

MGC has established licensed growing operations in the Czech Republic and Slovenia, a fully GMP certified resin extraction plant in Slovenia, and was the first company approval from the Maltese government to build a local medical cannabis cultivation and production facility.

KEY PEOPLE

Nativ Segev – Founder, Director

Nativ Segev has more than 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles. Previously, he served as CEO of a leading medical cannabis company with a large patient base.

Roby Zomer - Founder, Managing Director

Roby Zomer has 10 years’ experience in the biotech and agtech sectors and joined MGC Pharmaceuticals as executive director and CTO. He brings extensive business contacts and his scientific and engineering skillsets to ensure MGC’s position as a leader in research and development.

Brett Mitchell – Executive Chairman

Brett Mitchell is a corporate finance executive with over 20 years of experience in the finance and resources industries. He has been involved in the founding, financing and management of both private and publicly-listed resource companies and holds executive and non-executive directorship roles.

Dr. Jonathan Gruenfeld – Chief Scientific Officer

Certified in Israel, with clinical experience in at the M.D. Anderson Cancer Center, Dr. Grunfeld has spent the past twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cananabis as a treatment for oncological palliative care. He has directly been involved in the licensing and care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.